[HTML] frontiersin.org

[HTML][HTML] Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer

Z Hou, J Lin, Y Ma, H Fang, Y Wu, Z Chen… - Frontiers in …, 2023 - frontiersin.org
Introduction: Resistance to gemcitabine is common and critically limits its therapeutic
efficacy in pancreatic ductal adenocarcinoma (PDAC). Methods: We constructed 17 patient …
被引用次数：9 相关文章

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer

Z Hou, J Lin, Y Ma, H Fang, Y Wu, Z Chen… - Frontiers in …, 2023 - europepmc.org
Introduction: Resistance to gemcitabine is common and critically limits its therapeutic
efficacy in pancreatic ductal adenocarcinoma (PDAC). Methods: We constructed 17 patient …
[HTML] nih.gov

[HTML][HTML] Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer

Z Hou, J Lin, Y Ma, H Fang, Y Wu, Z Chen… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Introduction: Resistance to gemcitabine is common and critically limits its therapeutic
efficacy in pancreatic ductal adenocarcinoma (PDAC). Methods: We constructed 17 patient …

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer

Z Hou, J Lin, Y Ma, H Fang, Y Wu… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction: Resistance to gemcitabine is common and critically limits its therapeutic
efficacy in pancreatic ductal adenocarcinoma (PDAC). Methods: We constructed 17 patient …

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer.

Z Hou, J Lin, Y Ma, H Fang, Y Wu, Z Chen… - Frontiers in …, 2023 - europepmc.org
Introduction: Resistance to gemcitabine is common and critically limits its therapeutic
efficacy in pancreatic ductal adenocarcinoma (PDAC). Methods: We constructed 17 patient …